Citigroup Issues Positive Forecast for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price

Sarepta Therapeutics (NASDAQ:SRPT) had its price objective hoisted by Citigroup from $9.00 to $13.00 in a research note published on Thursday,Benzinga reports. They currently have a sell rating on the biotechnology company’s stock.

A number of other equities research analysts have also commented on SRPT. Wells Fargo & Company dropped their price objective on shares of Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating on the stock in a report on Friday, February 27th. Royal Bank Of Canada upped their target price on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the stock a “sector perform” rating in a research note on Thursday, January 8th. Loop Capital set a $25.00 target price on Sarepta Therapeutics in a report on Tuesday, March 3rd. Oppenheimer reissued an “outperform” rating and issued a $37.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, March 19th. Finally, Wedbush cut their price target on Sarepta Therapeutics from $34.00 to $29.00 and set an “outperform” rating on the stock in a report on Monday, March 2nd. Nine equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $32.30.

Sarepta Therapeutics Price Performance

NASDAQ SRPT opened at $21.68 on Thursday. The business has a 50 day simple moving average of $18.71 and a 200 day simple moving average of $19.97. Sarepta Therapeutics has a 52-week low of $10.41 and a 52-week high of $73.95. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.48 and a current ratio of 2.32. The stock has a market cap of $2.28 billion, a price-to-earnings ratio of -2.57, a PEG ratio of 0.37 and a beta of 0.42.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) EPS for the quarter, missing the consensus estimate of ($0.87) by ($2.71). The company had revenue of $442.93 million for the quarter, compared to analyst estimates of $390.95 million. Sarepta Therapeutics had a negative return on equity of 50.74% and a negative net margin of 38.34%.The business’s quarterly revenue was down 32.7% on a year-over-year basis. During the same quarter last year, the business posted $1.90 earnings per share. Analysts anticipate that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Stephen Mayo sold 7,239 shares of Sarepta Therapeutics stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $17.02, for a total value of $123,207.78. Following the sale, the director directly owned 1,765 shares in the company, valued at approximately $30,040.30. The trade was a 80.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in SRPT. Kestra Advisory Services LLC acquired a new position in shares of Sarepta Therapeutics during the 4th quarter worth about $25,000. iSAM Funds UK Ltd acquired a new stake in shares of Sarepta Therapeutics in the third quarter valued at about $25,000. Ancora Advisors LLC increased its position in shares of Sarepta Therapeutics by 200.0% in the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 1,000 shares during the last quarter. Byrne Asset Management LLC bought a new stake in Sarepta Therapeutics during the third quarter worth about $33,000. Finally, Allworth Financial LP boosted its position in Sarepta Therapeutics by 2,098.8% during the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 1,721 shares during the last quarter. 86.68% of the stock is owned by institutional investors.

Key Headlines Impacting Sarepta Therapeutics

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Early Phase 1/2 siRNA results point to target knockdown, muscle exposure and tolerability for SRP‑1001 and SRP‑1003 — the primary catalyst behind the rally. Business Wire: Sarepta Announces First Clinical Data
• Positive Sentiment: Multiple outlets and market commentators highlight the clinical readouts as a potential turning point; coverage helped drive heavy volume and momentum into the stock. Yahoo Finance: SRPT Stock Surges
• Positive Sentiment: Some sell‑side moves reflected renewed conviction — Morgan Stanley is reported to have raised its price target (reported widely alongside the trial coverage), which helped fuel the rally. InsiderMonkey: Morgan Stanley PT Hike
• Positive Sentiment: Unusually heavy options and call buying accompanied the move, indicating speculative bullish positioning and short‑term leverage from traders.
• Neutral Sentiment: Several valuation and note‑style writeups are trying to size the opportunity vs. risk — analysts and outlets caution that early Phase 1/2 data need confirmation and that valuation debate will drive near‑term swings. Yahoo/Zacks coverage: Is Further Upside Left?
• Negative Sentiment: Some firms remain skeptical — Citigroup raised a price target modestly but kept a sell rating (cites downside from current levels), and Needham reaffirmed an underperform stance, keeping sell‑side views polarized. Benzinga: Analyst Ratings
• Negative Sentiment: Independent analysts and commentators warn the data are early — some outlets argue it’s too soon to extrapolate durable clinical or commercial success from small Phase 1/2 cohorts. Seeking Alpha: Too Early to Get Excited
• Negative Sentiment: Underlying fundamentals and priorquarter results (recent EPS miss and revenue decline vs. year‑ago) remain a drag on sentiment; this increases the chance of volatility if follow‑up data or guidance disappoints.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.